A call to action: molecular pathology in Brazil

Table 2 PD-L1 IHC test by tumor type in available for use in Brazil currently

Primary site	Indication	AB	Cells	Method	Cut-offs
Lung	Pembrolizumab	22C3	TC	TPS	≥1% e ≥ 50%
Lung	Atezolizumab	SP142	TC + IC	%IC/tu area	≥50% (TC) ≥10% (IC)
Stomach/EGJ	Pembrolizumab	22C3	TC + IC	CPS	≥1
Uterine Cervix	Pembrolizumab	22C3	TC + IC	CPS	≥1
Urotelial Carcinoma	Pembrolizumab	22C3	TC + IC	CPS	≥10
Urotelial Carcinoma	Atezolizumab	SP142	IC	%IC/tumor area	≥5%
Head & Neck - SCC	Pembrolizumab	22C3	TC + IC	CPS	≥1 e ≥ 20
Breast	Atezolizumab	SP142	IC	%IC/tumor area	≥1%
Esophagus	Pembrolizumab	22C3	TC + IC	CPS	≥10

ISSN: 2520-8454